HLB Liver Cancer Drug Stumbles Again at FDA Over China Partner's Facility

HLB liver cancer drug hits FDA setback again over manufacturing issues

HLB's hopes of bringing its liver cancer treatment to the US market have suffered another blow after the US Food and Drug Administration iss

A Study of Combination Therapy in Patients With Resectable Liver Cancer

Conditions : Liver Cancer (Primary and Metastatic) Interventions : Drug: Hepatic Arterial Infusion Chemotherapy Combined with Adebrelimab Pl

<![CDATA[FDA Rejects Rivoceranib/Camrelizumab in First-Line Unresectable HCC]]>

HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma

Conditions : Liver Cancer Interventions : Device: DEB-TACE; Drug: Toripalimab; Drug: Lenvatinib; Drug: Gemcitabine; Drug: Oxaliplatin Sponso

Kailera’s oral GLP-1 asset sees 11% weight loss, hits goals in Chinese phase 3 obesity and diabetes trials

Phase 3 trials of Kailera Therapeutics’ oral GLP-1 prospect have hit their primary endpoints, positioning the biotech’s partner Hengrui Phar

恒瑞医药回应“双艾”组合再次延迟批准上市：未涉及产品安全性及有效性

恒瑞医药公告公司收到美国食品药品监督管理局关于注射用卡瑞利珠单抗联合甲磺酸阿帕替尼片用于不可切除或转移性肝细胞癌患者的一线治疗的生物制品许可申请的完整回复信。这也���“双艾”组合第三次被FDA延迟批准上市。对此，恒瑞医药回应称，“稳步推进国际化是公司的长期发展战略，公司多项创新